Eikon Therapeutics, Inc. (EIKN) Ownership
EIKN ownership summary
as of October 18, 2026- Institutions
- 69.6% of shares outstanding
- Insiders
- 17.38% of shares outstanding
- Shares outstanding
- 54.2M
- Float
- 34.8M shares available to trade
- Short interest
- 15.44% 6.3M shares short
- Days to cover
- 9.76 short interest up 15.4% vs prior month
- Institutions 69.64%
- Insiders 17.38%
- Other investors 12.98%
EIKN top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 9.22% | 5.0M | $37.1M | +1.2M (+30.2%) | June 30, 2026 |
| 2 | BlackRock Inc | 7.90% | 4.3M | $31.8M | +962,046 (+29.0%) | June 30, 2026 |
| 3 | Foresite Capital Management IV, LLC | 3.59% | 1.9M | $14.4M | — | June 30, 2026 |
| 4 | Merck & Co Inc | 3.08% | 1.7M | $12.4M | — | June 30, 2026 |
| 5 | T. Rowe Price Investment Management,Inc. | 2.95% | 1.6M | $11.8M | +372,787 (+30.5%) | June 30, 2026 |
| 6 | Foresite Capital Management V, LLC | 2.44% | 1.3M | $9.8M | — | June 30, 2026 |
| 7 | Capital World Investors | 2.17% | 1.2M | $8.7M | +32,307 (+2.8%) | June 30, 2026 |
| 8 | T. Rowe Price Associates, Inc. | 1.86% | 1.0M | $7.5M | +29,201 (+3.0%) | June 30, 2026 |
| 9 | Vanguard Capital Management, LLC | 1.70% | 923K | $6.8M | −46,724 (−4.8%) | June 30, 2026 |
| 10 | EcoR1 Capital, LLC | 1.35% | 733K | $5.4M | — | June 30, 2026 |
| 11 | AllianceBernstein L.P. | 1.19% | 642K | $4.8M | −380,300 (−37.2%) | June 30, 2026 |
| 12 | Geode Capital Management, LLC | 1.03% | 557K | $4.1M | +283,024 (+103.3%) | June 30, 2026 |
| 13 | Baker Bros Advisors LP | 1.03% | 556K | $4.1M | — | June 30, 2026 |
| 14 | SOROS CAPITAL MANAGEMENT LLC | 0.89% | 485K | $3.6M | — | June 30, 2026 |
| 15 | StepStone Group LLC | 0.73% | 395K | $2.9M | — | June 30, 2026 |
| 16 | Canada Pension Plan Investment Board | 0.70% | 379K | $2.8M | — | June 30, 2026 |
| 17 | State Street Corp | 0.65% | 354K | $2.6M | +313,943 (+781.9%) | June 30, 2026 |
| 18 | Franklin Templeton Inc | 0.65% | 350K | $2.6M | — | June 30, 2026 |
| 19 | General Catalyst Group Management, LLC | 0.56% | 305K | $2.3M | — | June 30, 2026 |
| 20 | UBS Group AG | 0.49% | 264K | $2.0M | +164,524 (+165.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 8 holders added 3.3M shares and 2 cut 427K.
EIKN top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BGF World Healthscience A2 | 2.81% | 1.5M | $11.3M | — | June 30, 2026 |
| 2 | Fidelity Contrafund | 2.35% | 1.3M | $9.5M | −416 (−0.0%) | August 31, 2026 |
| 3 | Fidelity Select Biotechnology | 2.16% | 1.2M | $8.7M | +18,200 (+1.6%) | August 31, 2026 |
| 4 | American Funds SMALLCAP World A | 2.11% | 1.1M | $8.5M | — | June 30, 2026 |
| 5 | T. Rowe Price Small-Cap Value | 1.57% | 849K | $6.3M | −7,778 (−0.9%) | August 31, 2026 |
| 6 | T. Rowe Price New Horizons | 1.53% | 831K | $6.2M | −27,722 (−3.2%) | August 31, 2026 |
| 7 | iShares Russell 2000 ETF | 1.50% | 810K | $6.0M | −9,344 (−1.1%) | September 30, 2026 |
| 8 | Fidelity Growth Company Fund | 1.35% | 731K | $5.4M | +97,600 (+15.4%) | August 31, 2026 |
| 9 | BlackRock Health Sciences Opps Inv A | 1.33% | 722K | $5.4M | — | August 31, 2026 |
| 10 | T. Rowe Price Health Sciences | 1.33% | 721K | $5.3M | +1 (+0.0%) | August 31, 2026 |
| 11 | Vanguard MStar Total Stk Mkt Idx Invest | 1.22% | 660K | $4.9M | — | August 31, 2026 |
| 12 | AB Small Cap Growth A | 0.82% | 442K | $3.3M | −3,624 (−0.8%) | August 31, 2026 |
| 13 | Fidelity Contrafund K6 | 0.49% | 265K | $2.0M | −645 (−0.2%) | August 31, 2026 |
| 14 | Fidelity Small Cap Index | 0.44% | 238K | $1.8M | +1,876 (+0.8%) | July 31, 2026 |
| 15 | Franklin Biotechnology Discv A(acc)USD | 0.41% | 223K | $1.7M | — | August 31, 2026 |
| 16 | Fidelity Growth Company K6 | 0.38% | 207K | $1.5M | +28,000 (+15.6%) | August 31, 2026 |
| 17 | iShares Russell 2000 Growth ETF | 0.38% | 204K | $1.5M | −258 (−0.1%) | September 30, 2026 |
| 18 | Fidelity Series Growth Company | 0.35% | 187K | $1.4M | +24,800 (+15.3%) | August 31, 2026 |
| 19 | Schwab US Small-Cap ETF™ | 0.28% | 152K | $1.1M | +99 (+0.1%) | September 30, 2026 |
| 20 | Principal SmallCap Growth I Instl | 0.26% | 141K | $1.0M | +683 (+0.5%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
Who owns EIKN
Institutional investors own 69.6% of Eikon Therapeutics's shares and insiders 17.38%. The largest holder is FMR Inc with 9.22% of the shares (5.0M), as of June 30, 2026. Among the top 20 institutions, 8 added shares and 2 reduced their stake in the latest filings. Short interest is 15.44% of the float, or 9.76 days of average trading volume.
Related: EIKN analyst forecast, EIKN key metrics. See the EIKN stock overview for the latest quote and news.
EIKN ownership FAQ
Who owns the most Eikon Therapeutics stock?
The largest shareholders of Eikon Therapeutics are FMR Inc (9.22%), BlackRock Inc (7.90%), Foresite Capital Management IV, LLC (3.59%), Merck & Co Inc (3.08%), T. Rowe Price Investment Management,Inc. (2.95%).
What percentage of Eikon Therapeutics is owned by institutions?
Institutions hold 69.6% of Eikon Therapeutics's shares outstanding; insiders hold 17.38%.
Which funds own Eikon Therapeutics?
The largest fund holders of Eikon Therapeutics are BGF World Healthscience A2 (2.81%), Fidelity Contrafund (2.35%), Fidelity Select Biotechnology (2.16%), American Funds SMALLCAP World A (2.11%), T. Rowe Price Small-Cap Value (1.57%).
What is Eikon Therapeutics's short interest?
6.3M shares of Eikon Therapeutics were sold short, 15.44% of the float; at the average daily volume it would take 9.76 days to cover.
How many shares of Eikon Therapeutics are outstanding?
Eikon Therapeutics has 54.2M shares outstanding, of which 34.8M are in the public float.